Biochemical, histopathological and behavioral alterations caused by intrastriatal administration of quinolic acid to young rats

FEBS Journal

Volumn 281, Issue 8, 2014, Pages 2061-2073

  Pierozan, Paula ^a   Fernandes, Carolina G ^a   Dutra, Márcio F ^a,b   Pandolfo, Pablo ^a,c   Ferreira, Fernanda ^a   De Lima, Bárbara O ^a   Porciúncula, Lisiane ^a   Wajner, Moacir ^a   Pessoa Pureur, Regina ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^c FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

astrogliosis; excitotoxicity; neurodegeneration; quinolinic acid; striatum

Indexed keywords

ANTHRANILIC ACID DERIVATIVE; CALCIUM; GLUTAMIC ACID; QUINOLIC ACID; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; BRAIN CORTEX; CALCIUM TRANSPORT; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; EXCITOTOXICITY; HIPPOCAMPUS; HISTOPATHOLOGY; MOTOR DYSFUNCTION; NERVE CELL NECROSIS; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; RAT;

ASTROGLIOSIS; EXCITOTOXICITY; NEURODEGENERATION; QUINOLINIC ACID; STRIATUM;

ANIMALS; BEHAVIOR, ANIMAL; CORPUS STRIATUM; HIPPOCAMPUS; NEUROPROTECTIVE AGENTS; QUINOLINIC ACID; RATS; RATS, WISTAR;

EID: 84899439812     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12762     Document Type: Article

References (59)

1. Stone TW, &, Perkins MN, (1981) Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur J Pharmacol 72, 411-412.
2. Chen Y, &, Guillemin GJ, (2009) Kynurenine pathway metabolites in humans: disease and healthy states. Int J Tryptophan Res 2, 1-19.
3. Guillemin GJ, Smythe G, Takikawa O, &, Brew BJ, (2005) Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 49, 15-23.
4. Kohler C, Eriksson LG, Okuno E, &, Schwarcz R, (1988) Localization of quinolinic acid metabolizing enzymes in the rat brain. Immunohistochemical studies using antibodies to 3-hydroxyanthranilic acid oxygenase and quinolinic acid phosphoribosyltransferase. Neuroscience 27, 49-76.
5. Lugo-Huitron R, Ugalde Muniz P, Pineda B, Pedraza-Chaverri J, Rios C, &, Perez-de la Cruz V, (2013) Quinolinic acid: an endogenous neurotoxin with multiple targets. Oxid Med Cell Longev 2013, 104024.
6. Foster AC, Zinkand WC, &, Schwarcz R, (1985) Quinolinic acid phosphoribosyltransferase in rat brain. J Neurochem 44, 446-454.
7. Tan L, &, Yu JT, (2012) The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations. J Neurol Sci 323, 1-8.
8. Perez-De La Cruz V, Elinos-Calderon D, Robledo-Arratia Y, Medina-Campos ON, Pedraza-Chaverri J, Ali SF, &, Santamaria A, (2009) Targeting oxidative/nitrergic stress ameliorates motor impairment, and attenuates synaptic mitochondrial dysfunction and lipid peroxidation in two models of Huntington's disease. Behav Brain Res 199, 210-217.
9. Pérez-De La Cruz V, Carrillo-Mora P, &, Santamaría A, (2012) Quinolinic acid, an endogenous molecule combining excitotoxicity, oxidative stress and other toxic mechanisms. Int J Tryptophan Res 5, 1-8.
10. Knight RA, &, Verkhratsky A, (2010) Neurodegenerative diseases: failures in brain connectivity? Cell Death Differ 17, 1069-1070.
11. Li L, Lundkvist A, Andersson D, Wilhelmsson U, Nagai N, Pardo AC, Nodin C, Stahlberg A, Aprico K, Larsson K, et al,. (2008) Protective role of reactive astrocytes in brain ischemia. J Cereb Blood Flow Metab 28, 468-481.
12. Pekny M, &, Nilsson M, (2005) Astrocyte activation and reactive gliosis. Glia 50, 427-434.
13. Bushong EA, Martone ME, &, Ellisman MH, (2004) Maturation of astrocyte morphology and the establishment of astrocyte domains during postnatal hippocampal development. Int J Dev Neurosci 22, 73-86.
14. Bushong EA, Martone ME, Jones YZ, &, Ellisman MH, (2002) Protoplasmic astrocytes in CA1 stratum radiatum occupy separate anatomical domains. J Neurosci 22, 183-192.
15. Schwarcz R, &, Meldrum B, (1985) Excitatory aminoacid antagonists provide a therapeutic approach to neurological disorders. Lancet 2, 140-143.
16. Schwarcz R, &, Pellicciari R, (2002) Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther 303, 1-10.
17. Dugan LL, &, Kim-Han JS, (2006) Hypoxic-ischemic brain injury and oxidative stress. Basic Neurochemistry: Molecular, Cellular and Medical Aspects, pp. 563-569. Elsevier Academic Press, New York, NY.
18. Sánchez AME, Mejía-Toiber J, &, Massieu L, (2008) Excitotoxic neuronal death and the pathogenesis of Huntington's disease. Arch Med Res 39, 265-276.
19. Beal MF, Ferrante RJ, Swartz KJ, &, Kowall NW, (1991) Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J Neurosci 11, 1649-1659.
20. Scattoni ML, Valanzano A, Popoli P, Pezzola A, Reggio R, &, Calamandrei G, (2004) Progressive behavioural changes in the spatial open-field in the quinolinic acid rat model of Huntington's disease. Behav Brain Res 152, 375-383.
21. Kalonia H, Mishra J, &, Kumar A, (2012) Targeting neuro-inflammatory cytokines and oxidative stress by minocycline attenuates quinolinic-acid-induced Huntington's disease-like symptoms in rats. Neurotox Res 22, 310-320.
22. Sadan O, Shemesh N, Barzilay R, Dadon-Nahum M, Blumenfeld-Katzir T, Assaf Y, Yeshurun M, Djaldetti R, Cohen Y, Melamed E, et al,. (2012) Mesenchymal stem cells induced to secrete neurotrophic factors attenuate quinolinic acid toxicity: a potential therapy for Huntington's disease. Exp Neurol 234, 417-427.
23. Colle D, Hartwig JM, Soares FA, &, Farina M, (2012) Probucol modulates oxidative stress and excitotoxicity in Huntington's disease models in vitro. Brain Res Bull 87, 397-405.
24. Pierozan P, Zamoner A, Soska AK, Silvestrin RB, Loureiro SO, Heimfarth L, Mello e Souza T, Wajner M, &, Pessoa-Pureur R, (2010) Acute intrastriatal administration of quinolinic acid provokes hyperphosphorylation of cytoskeletal intermediate filament proteins in astrocytes and neurons of rats. Exp Neurol 224, 188-196.
25. Guidetti P, &, Schwarcz R, (1999) 3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum. Eur J Neurosci 11, 3857-3863.
26. Moresco RM, &, Fazio F, (2005) Molecular imaging of individual behaviour. Eur J Nucl Med Mol Imaging 32, 717-719.
27. Figueredo-Cardenas G, Chen Q, &, Reiner A, (1997) Age-dependent differences in survival of striatal somatostatin-NPY-NADPH-diaphorase-containing interneurons versus striatal projection neurons after intrastriatal injection of quinolinic acid in rats. Exp Neurol 146, 444-457.
28. Sun Z, Chen Q, &, Reiner A, (2003) Enkephalinergic striatal projection neurons become less affected by quinolinic acid than substance P-containing striatal projection neurons as rats age. Exp Neurol 184, 1034-1042.
29. Parpura V, Basarsky TA, Liu F, Jeftinija K, Jeftinija S, &, Haydon PG, (1994) Glutamate-mediated astrocyte-neuron signalling. Nature 369, 744-747.
30. Ehara A, &, Ueda S, (2009) Application of Fluoro-Jade C in acute and chronic neurodegeneration models: utilities and staining differences. Acta Histochem Cytochem 42, 171-179.
31. Guillemin GJ, (2012) Quinolinic acid, the inescapable neurotoxin. FEBS J 279, 1356-1365.
32. Olivera-Bravo S, Fernandez A, Sarlabos MN, Rosillo JC, Casanova G, Jimenez M, &, Barbeito L, (2011) Neonatal astrocyte damage is sufficient to trigger progressive striatal degeneration in a rat model of glutaric acidemia-I. PLoS One 6, e20831.
33. Brickell KL, Nicholson LF, Waldvogel HJ, &, Faull RL, (1999) Chemical and anatomical changes in the striatum and substantia nigra following quinolinic acid lesions in the striatum of the rat: a detailed time course of the cellular and GABA(A) receptor changes. J Chem Neuroanat 17, 75-97.
34. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, &, Martin JB, (1986) Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321, 168-171.
35. Shelbourne P, Coote E, Dadak S, &, Cobb SR, (2007) Normal electrical properties of hippocampal neurons modelling early Huntington disease pathogenesis. Brain Res 1139, 226-234.
36. Kremer HP, Roos RA, Dingjan G, Marani E, &, Bots GT, (1990) Atrophy of the hypothalamic lateral tuberal nucleus in Huntington's disease. J Neuropathol Exp Neurol 49, 371-382.
37. Holopainen IE, (2008) Seizures in the developing brain: cellular and molecular mechanisms of neuronal damage, neurogenesis and cellular reorganization. Neurochem Int 52, 935-947.
38. Albin RL, Reiner A, Anderson KD, Penney JB, &, Young AB, (1990) Striatal and nigral neuron subpopulations in rigid Huntington's disease: implications for the functional anatomy of chorea and rigidity-akinesia. Ann Neurol 27, 357-365.
39. Spear LP, (2000) The adolescent brain and age-related behavioral manifestations. Neurosci Biobehav Rev 24, 417-463.
40. Thiel CM, Muller CP, Huston JP, &, Schwarting RK, (1999) High versus low reactivity to a novel environment: behavioural, pharmacological and neurochemical assessments. Neuroscience 93, 243-251.
41. Paulsen JS, Ready RE, Hamilton JM, Mega MS, &, Cummings JL, (2001) Neuropsychiatric aspects of Huntington's disease. J Neurol Neurosurg Psychiatry 71, 310-314.
42. Furtado JC, &, Mazurek MF, (1996) Behavioral characterization of quinolinate-induced lesions of the medial striatum: relevance for Huntington's disease. Exp Neurol 138, 158-168.
43. Haik KL, Shear DA, Schroeder U, Sabel BA, &, Dunbar GL, (2000) Quinolinic acid released from polymeric brain implants causes behavioral and neuroanatomical alterations in a rodent model of Huntington's disease. Exp Neurol 163, 430-439.
44. Ransome MI, &, Hannan AJ, (2012) Behavioural state differentially engages septohippocampal cholinergic and GABAergic neurons in R6/1 Huntington's disease mice. Neurobiol Learn Mem 97, 261-270.
45. Pierozan P, Zamoner A, Soska AK, de Lima BO, Reis KP, Zamboni F, Wajner M, &, Pessoa-Pureur R, (2012) Signaling mechanisms downstream of quinolinic acid targeting the cytoskeleton of rat striatal neurons and astrocytes. Exp Neurol 233, 391-399.
46. Squitieri F, Frati L, Ciarmiello A, Lastoria S, &, Quarrell O, (2006) Juvenile Huntington's disease: does a dosage-effect pathogenic mechanism differ from the classical adult disease? Mech Ageing Dev 127, 208-212.
47. Myers RH, Vonsattel JP, Stevens TJ, Cupples LA, Richardson EP, Martin JB, &, Bird ED, (1988) Clinical and neuropathologic assessment of severity in Huntington's disease. Neurology 38, 341-347.
48. Butters N, Sax D, Montgomery K, &, Tarlow S, (1978) Comparison of the neuropsychological deficits associated with early and advanced Huntington's disease. Arch Neurol 35, 585-589.
49. Paxinos G, Watson C, Pennisi M, &, Topple A, (1985) Bregma, lambda and the interaural midpoint in stereotaxic surgery with rats of different sex, strain and weight. J Neurosci Methods 13, 139-143.
50. Qin Y, Soghomonian JJ, &, Chesselet MF, (1992) Effects of quinolinic acid on messenger RNAs encoding somatostatin and glutamic acid decarboxylases in the striatum of adult rats. Exp Neurol 115, 200-211.
51. Frizzo ME, Lara DR, Prokopiuk Ade S, Vargas CR, Salbego CG, Wajner M, &, Souza DO, (2002) Guanosine enhances glutamate uptake in brain cortical slices at normal and excitotoxic conditions. Cell Mol Neurobiol 22, 353-363.
52. 2+ uptake in cerebral cortex from young rats. Neurosci Res 57, 98-103.
53. Lowry OH, Rosebrough NJ, Farr AL, &, Randall RJ, (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193, 265-275.
54. Heimfarth L, Loureiro SO, Dutra MF, Petenuzzo L, de Lima BO, Fernandes CG, da Rocha JB, &, Pessoa-Pureur R, (2013) Disrupted cytoskeletal homeostasis, astrogliosis and apoptotic cell death in the cerebellum of preweaning rats injected with diphenyl ditelluride. Neurotoxicology 34, 175-188.
55. Rodgers RJ, (1997) Animal models of 'anxiety': where next? Behav Pharmacol 8, 477-496; discussion 497-504.
56. Ennaceur A, &, Delacour J, (1988) A new one-trial test for neurobiological studies of memory in rats. 1: behavioral data. Behav Brain Res 31, 47-59.
57. Pamplona FA, Pandolfo P, Savoldi R, Prediger RD, &, Takahashi RN, (2009) Environmental enrichment improves cognitive deficits in spontaneously hypertensive rats (SHR): relevance for attention deficit/hyperactivity disorder (ADHD). Prog Neuropsychopharmacol Biol Psychiatry 33, 1153-1160.
58. Dellu F, Fauchey V, Le Moal M, &, Simon H, (1997) Extension of a new two-trial memory task in the rat: influence of environmental context on recognition processes. Neurobiol Learn Mem 67, 112-120.
59. Pandolfo P, Machado NJ, Kofalvi A, Takahashi RN, &, Cunha RA, (2011) Caffeine regulates frontocorticostriatal dopamine transporter density and improves attention and cognitive deficits in an animal model of attention deficit hyperactivity disorder. Eur Neuropsychopharmacol 23, 317-328.